These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24401277)

  • 1. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.
    Bournazos S; Chow SK; Abboud N; Casadevall A; Ravetch JV
    J Clin Invest; 2014 Feb; 124(2):725-9. PubMed ID: 24401277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.
    DiLillo DJ; Tan GS; Palese P; Ravetch JV
    Nat Med; 2014 Feb; 20(2):143-51. PubMed ID: 24412922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent Requirement of Fc-Fcγ Receptor Interactions for
    Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
    Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
    Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.
    Van den Hoecke S; Ehrhardt K; Kolpe A; El Bakkouri K; Deng L; Grootaert H; Schoonooghe S; Smet A; Bentahir M; Roose K; Schotsaert M; Schepens B; Callewaert N; Nimmerjahn F; Staeheli P; Hengel H; Saelens X
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.
    Lim NK; Kim JH; Oh MS; Lee S; Kim SY; Kim KS; Kang HJ; Hong HJ; Inn KS
    Infect Immun; 2005 Oct; 73(10):6547-51. PubMed ID: 16177329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.
    Vitale L; Blanset D; Lowy I; O'Neill T; Goldstein J; Little SF; Andrews GP; Dorough G; Taylor RK; Keler T
    Infect Immun; 2006 Oct; 74(10):5840-7. PubMed ID: 16988263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.
    Loyau J; Malinge P; Daubeuf B; Shang L; Elson G; Kosco-Vilbois M; Fischer N; Rousseau F
    MAbs; 2014; 6(6):1621-30. PubMed ID: 25484053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-retroviral antibody FcγR-mediated effector functions.
    Bournazos S; Ravetch JV
    Immunol Rev; 2017 Jan; 275(1):285-295. PubMed ID: 28133801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
    Tada M; Aoyama M; Ishii-Watabe A
    J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
    Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
    Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
    Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
    MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
    Caaveiro JM; Kiyoshi M; Tsumoto K
    Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
    Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
    Front Immunol; 2019; 10():562. PubMed ID: 30984171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
    Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
    J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions.
    Cambay F; Henry O; Durocher Y; De Crescenzo G
    MAbs; 2019 Apr; 11(3):435-452. PubMed ID: 30822189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.